Safety and effectiveness of thalidomide and hydroxyurea combination in β‐thalassaemia intermedia and major: a retrospective pilot study

@article{Shah2019SafetyAE,
  title={Safety and effectiveness of thalidomide and hydroxyurea combination in $\beta$‐thalassaemia intermedia and major: a retrospective pilot study},
  author={Sandip Shah and Radhika Sheth and Kamlesh M. Shah and Kinnari A Patel},
  journal={British Journal of Haematology},
  year={2019},
  volume={188}
}
Adams Waldorf, K.M. & Nelson, J.L. (2008) Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy. Immunological Investigations, 37, 631–644. Akinlaja, O. (2016) Hematological changes in pregnancy – the preparation for intrapartum blood loss. Obstetrics & Gynecology International Journal, 4, 00109. Arneborn, P. & Palmblad, J. (1982) Drug-induced neutropenia – a survey for Stockholm 1973– 1978. Acta Medica Scandinavica, 212, 289–292. Boxer, L.A., Bolyard, A.A., Kelley, M.L… Expand
7 Citations

Topics from this paper

Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study
  • Xinyu Li, Shuting Hu, +5 authors Jianpei Fang
  • Medicine
  • Frontiers in Pharmacology
  • 2021
TLDR
The dose of thalidomide between 2.5 mg·kg-1·d-1 and 3.6 mg· kg-1-d- 1 is effective in TDT children and HbF concentration of 47.298 g·L-1 at the third month is recommended as the predictor for further major responders. Expand
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients
TLDR
Nearly three-fourth of the patients has responded with majority having CR, and Adverse events are a concern; hence, regular close monitoring is a prerequisite. Expand
Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia
TLDR
Thalidomide resulted in major/moderate response in majority of children with transfusion-dependent thalassemia with satisfactory adverse effect profile. Expand
Alternative Strategies in Thalassemia: Focus on Thalidomide
TLDR
Thalidomide has been shown to increase hemoglobin F levels through inducing c-globin mRNA expression in a dose-dependent manner by increasing intracellular reactive oxygen species and is known for its immune-modulating and anti-angiogenic properties. Expand
2021 update on clinical trials in β‐thalassemia
The treatment landscape for patients with β‐thalassemia is witnessing a swift evolution, yet several unmet needs continue to persist. Patients with transfusion‐dependent β‐thalassemia (TDT) primarilyExpand
Challenges in transfusion and the role of Thalidomide in E‐β‐Thalassemia—A case report
TLDR
This case illustrates the role of thalidomide in transfusions‐sparing therapies in patients with transfusion‐dependent thalassemia and challenges in the blood bank with severe anemia and multiple allo‐antibodies. Expand
Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases
TLDR
Deferiprone, deferoxamine, deferasirox and other chelating drugs can offer therapeutic solutions for most diseases associated with iron metabolism including iron overload and deficiency, neurodegeneration and cancer, the detoxification of xenobiotic metals and most diseasesassociated with free radical pathology. Expand

References

SHOWING 1-10 OF 13 REFERENCES
Clinical and Haematological Effects of Hydroxyurea in β-Thalassemia Intermedia Patients.
TLDR
In patients with thalassemia intermedia, HU significantly diminished the rate of transfusion, hospitalization, spleen size and significantly increased Hb MCH, HbF and MCV, without any remarkable adverse events. Expand
Thalassaemia Intermedia: an Update
TLDR
There are a number of options currently available for managing patients with TI, including transfusion therapy, iron chelation therapy, modulation of foetal haemoglobin production and haematopoietic stem cell transplantation, but at present there are no clear guidelines for an orchestrated optimal treatment plan. Expand
Current and future alternative therapies for beta-thalassemia major
TLDR
Novel approaches are being developed to correct the resulting α/β-globin chain imbalance in beta-thalassemia, in an effort to move beyond the palliative management of this disease and the complications of its treatment (e.g. life-long red blood cell transfusion, iron chelation, splenectomy). Expand
Foetal haemoglobin inducers and thalassaemia: novel achievements.
  • R. Gambari
  • Medicine
  • Blood transfusion = Trasfusione del sangue
  • 2010
TLDR
The case reported in this issue of the journal by Masera et al. on the impressive response to thalidomide in a thalassaemia major patient carrying a IVS1-6/cd44-C genotype and resistant to conventional therapy is of great interest, especially when considered together with other recent reports in the field of induction of HbF in patients affected by β-thalassaemic. Expand
Beta-thalassemia
TLDR
Prognosis for individuals with beta-thalassemia has improved substantially in the last 20 years following recent medical advances in transfusion, iron chelation and bone marrow transplantation therapy, however, cardiac disease remains the main cause of death in patients with iron overload. Expand
Novel and innovative approaches to the treatment of β-thalassemia
TLDR
Even though the future looks promising, carefully designed clinical trials in adults and children, with suitable end-points are still needed to confirm the efficacy, toxicity, and improvements in quality of life of patients with β-thalassemia. Expand
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
TLDR
This consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and transplant management. Expand
Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis.
TLDR
Data indicate that thalidomide induces increased expression of the gamma-globin gene via ROS-dependent activation of the p38 MAPK signaling pathway and histone H4 acetylation. Expand
Novel and innovative approaches
  • 2017
Novel and innovative approaches for treatment of b-thalassemia
  • Pediatric Hematology and Oncology
  • 2017
...
1
2
...